November 2026 INVESTOR PRESENTATION NASDAQ: NUWE

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 November 2026 INVESTOR PRESENTATION NASDAQ: NUWE NASDAQ: NUWE Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange A

Original reporting
Published Nov 17, 2026, 1:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NUWE
Bullish
medium confidence
Mentioned
$NUWE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NUWEBullishLow
01

Why it matters

The presentation provides decision-relevant operating snapshots (YTD revenue growth, gross margin improvement, and cash runway) that can influence positioning, but it is not a new earnings release or a definitive forward guidance update.

02

Market read

Traders may use the disclosed runway and margin trajectory to reassess near-term financing risk and growth momentum, but the lack of a new catalyst likely limits immediate repricing.

03

What to watch

Cash runway through Q2 2027 reduces near-term financing risk, but investors may still scrutinize whether adoption and margin expansion are sustainable and whether label expansion timelines translate into revenue acceleration.

Relevance 4/10Novelty 4/10Timing: filed on 2026-11-17, pre-market/early session availability

Background

The 8-K is a Regulation FD disclosure furnishing NUWE’s November 2026 investor presentation focused on Aquadex ultrafiltration, pediatric growth, and financial runway.

Company-level read

Ticker impact

$NUWEBullishMedium confidence
Context

NUWE filed an 8-K with its November 2026 investor presentation highlighting Aquadex growth, margins, and cash runway through Q2 2027.

Expected impact

Likely modest upward bias as investors focus on runway and margin improvement, but reaction may be limited because this is primarily a marketing-style update rather than fresh audited results.

Evidence & confidence

The filing is a Regulation FD disclosure (investor deck) with specific operating metrics (YTD revenue growth, gross margin, cash runway) but no new guidance, trial readout, or capital raise terms.

Market effects

Reinforces investor attention on ultrafiltration and cardiorenal solutions in hospital settings, but does not introduce new sector-wide regulatory or competitive shocks.

Primarily US healthcare/hospital procurement narrative; no direct regional macro linkage.

Limited, as the deck focuses on US addressable market and US revenue metrics.

Counterpoint

Deck metrics may reflect prior trends and assumptions; without new clinical endpoints, reimbursement updates, or formal guidance, the market may discount the impact.

Key entities

  • Nuwellis, Inc.

    NUWE, provider of Aquadex ultrafiltration system; furnished investor presentation via 8-K Item 7.01.

  • Aquadex

    Clinically proven ultrafiltration system for precise fluid removal; central to the deck’s growth and margin narrative.

Related articles

$NUWEMed

Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in…

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss Console unit sales increased 88% year-to-date versus pri

$NUWEHighAI 8/10

Nuwellis submits FDA application for pediatric Aquadex expansion

Nuwellis (NASDAQ: NUWE) submitted a 510(k) application to the FDA to expand the use of its Aquadex SmartFlow System to pediatric patients weighing 5 kg and above, currently cleared for 20 kg and above. The submission includes clinical data from the ULTRA-Peds Registry and aims to provide treatment options for fluid overload in smaller children. The company's CEO and a medical director commented on the strategic importance and clinical benefits of the expansion.

$NUWEMed

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 13, 2026 Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin Recent capital raise and warrant exercises extend cash runway through second quarter

$NUWEMed

Nuwellis Slumps on Share Sale

Nuwellis (NASDAQ: NUWE) entered a definitive securities purchase agreement for a registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds of about $3.1 million from warrant exercises tied to its June 2026 offering. In a concurrent private placement, investors receive warrants for up to 1,310,890 shares at $2.59, exercisable immediately, expiring in five years. Closing expected around Aug. 3, 2026.

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.